# A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.

> **NCT01485926** · PHASE2 · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 120 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel, Carboplatin and Trastuzumab
- **DRUG:** Docetaxel, Carboplatin, Trastuzumab and Lapatinib

## Key facts

- **NCT ID:** NCT01485926
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-09
- **Final completion:** 2018-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2018-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01485926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01485926, "A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01485926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*